CSTDs for Drug Preparation

August 2021 - Vol.18 No. 8 - Page #40
Category: Closed System Drug-Transfer Devices (CSTDs)

Progress toward full adoption of CSTDs for drug preparation across facilities of all sizes continued even through the pandemic. Notable developments in this marketplace include the introduction of BD’s PhaSeal Optima and Fresenius Kabi’s purchase of Corvida’s Halo. Pharmacy’s additional purchasing plans mean this market will remain robust over the near term.

For more information, visit pppmag.com/automation and select Compounding, then CSTDs.


While the majority of CSTD users are committed to their current vendor, it is notable that more than 4 out of 10 users would consider switching to a new vendor.


For those facilities planning to purchase CSTDs for the first time and those who are open to switching to a new vendor, BD, Equashield, and ICU Medical are the leading vendors under consideration.


The leading devices under consideration are Equashield, BD’s PhaSeal, BD’s PhaSeal Optima, and ICU Medical’s ChemoClave.

Click here to view a larger version of this chart.


Login

Like what you've read? Please log in or create a free account to enjoy more of what www.pppmag.com has to offer.

Current Issue